Singapore markets closed

Mersana Therapeutics, Inc. (MRSN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
4.4800-0.0100 (-0.22%)
At close: 04:00PM EDT
4.4800 0.00 (0.00%)
After hours: 05:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close4.4900
Open4.5100
Bid4.4700 x 200
Ask4.5300 x 200
Day's range4.4700 - 4.7100
52-week range0.8010 - 9.6200
Volume1,315,262
Avg. volume2,362,808
Market cap543.437M
Beta (5Y monthly)1.51
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results

    Enrollment in dose escalation and backfill cohorts continuing in Phase 1 clinical trial of XMT-1660; expect to initiate tumor-specific expansion cohorts in the second quarter of 2024 and announce initial clinical data in mid-2024Phase 1 clinical trial of XMT-2056 restarting; plan to advance dose escalation in 2024 Continue to expect capital resources will support current operating plan commitments into 2026Conference call today at 8:00 a.m. ET CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) --

  • GlobeNewswire

    Mersana Therapeutics to Present at Upcoming Investor Conferences

    CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that members of management will present at the following upcoming investor conferences: TD Cowen 44th Annual Health Care Conference Format:Panel discussionDate/Time:Tuesday, March 5, 2024, at 9:10 a.m. Easte

  • GlobeNewswire

    Mersana Therapeutics to Host Fourth Quarter and Year End 2023 Conference Call on February 28, 2024

    CAMBRIDGE, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the fourth quarter and full year ended December 31, 2023 on Wednesday, February 28, 2024. The company will host a conference call an